High Dose Risankizumab for Psoriasis
Completed · Phase 2 · NCT05283135
Conditions: Psoriasis
At a glance
- Research payments reported, 2025
- $23,550
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Oregon Medical Research Center (with AbbVie)
- Tested
- risankizumab (drug)
- Dates
- Started 2022-03-01; completion 2024-07-10
- Results posted
- Yes
This pilot study explores higher than standard doses of risankizumab for plaque psoriasis, to see effects on resident memory T cells and skin clearance.
From ClinicalTrials.gov, last updated 2025-10-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $23,550 in research payments for this study in 2025 (2 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Andrew Blauvelt, MD Dermatology · Portland, OR
- Benjamin D. Ehst, M.D., PH.D. Dermatology · Portland, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Oregon Med Research Ctr P $20,000
- Oregon Med Research Ctr $3,550
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.